Sionna Therapeutics develops experimental medicines for cystic fibrosis, a genetic disease that affects the lungs and other organs. SION reports earnings on Wed, Nov 4, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 15 | Wedbush | Target raised | Hold | |
| Aug 11 | Wedbush | Downgrade | Hold | |
| Aug 7 | Guggenheim | Maintained | Buy | |
| May 20 | Freedom Broker | Downgrade | Hold | |
| May 18 | Stifel | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in SION in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SION is in one of them and how their past SION trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SION in an article yet. Here's the latest on the wider market.
About Sionna Therapeutics
Sionna Therapeutics is a drug developer based in Waltham, Massachusetts. It is developing medicines for people with cystic fibrosis, an inherited disease that causes thick mucus to build up in the lungs, pancreas and other organs. Its candidates are designed to stabilize a part of the CFTR protein called NBD1, which is affected by the most common cystic fibrosis mutation. The company is still testing these candidates in clinical trials.
- Headquarters
- Waltham, MA